哌罗匹隆与利培酮治疗首发性精神分裂症的临床疗效与安全性对照研究
|
摘要
目的探讨并总结哌罗匹隆与利培酮对于首发精神分裂症患者的临床有效性和安全性,进一步寻求更好的精神分裂症的治疗方法。方法选取2012年1月~2013年10月华中科技大学同济医学院附属精神卫生中心精神科的首发精神分裂症的患者80例,随机均分为实验组和对照组(n=40)。实验组采用哌罗匹隆进行治疗,对照组采用利培酮进行治疗,对比2组患者的临床疗效、安全性及患者和家属对治疗的满意情况。结果实验组患者的临床有效率为87.50%,不良反应发生率为42.50%,患者的满意度为82.50%;对照组患者的临床有效率为80.00%,不良反应发生率为52.50%,患者的满意度为75.00%。2组比较,差异均有统计学意义(P<0.05)。结论哌罗匹隆对首发精神分裂症的患者的临床疗效较好,不良反应较轻,且患者对治疗的满意度高,有较好的临床意义及推广价值。
Objective To discuss and summarize clinical effectiveness and safety of perospirone and risperidone for treatment of fi rst-episode schizophrenia and look for a better treatment method. Methods 80 patients with fi rst-episode schizophrenia were randomly divided into 2 groups both with 40 cases. Experiment group was given perospirone for treatment while control group was given risperidone for treatment. Clinical effects, safety and satisfaction degree of patients and their families of the 2 groups were compared. Results Clinical effective rate of experiment group was 87.50% and adverse effect occurrence rate was 42.50% and satisfaction degree of patients was 82.50%; Clinical effective rate of experiment group was 80.00% and adverse effect occurrence rate was 52.50% and satisfaction degree of patients was 70.00%(P<0.05). Conclusion Perospirone has a good clinical effect for treatment of fi rst-episode schizophrenia with light adverse effects and high satisfaction degree of patients, so it has good clinical signifi cance and promotional value.
Objective To discuss and summarize clinical effectiveness and safety of perospirone and risperidone for treatment of fi rst-episode schizophrenia and look for a better treatment method. Methods 80 patients with fi rst-episode schizophrenia were randomly divided into 2 groups both with 40 cases. Experiment group was given perospirone for treatment while control group was given risperidone for treatment. Clinical effects, safety and satisfaction degree of patients and their families of the 2 groups were compared. Results Clinical effective rate of experiment group was 87.50% and adverse effect occurrence rate was 42.50% and satisfaction degree of patients was 82.50%; Clinical effective rate of experiment group was 80.00% and adverse effect occurrence rate was 52.50% and satisfaction degree of patients was 70.00%(P<0.05). Conclusion Perospirone has a good clinical effect for treatment of fi rst-episode schizophrenia with light adverse effects and high satisfaction degree of patients, so it has good clinical signifi cance and promotional value.
引文
[1]朱桂东,徐松泉,周云芳,等.哌罗匹隆与奎硫平治疗首发精神分裂症临床对照[J].医药导报,2011,30(4):477-478.
[2]宋梓祥,涂德华,潘佳,等.奥氮平与利培酮治疗难治性精神分裂症的对照研究[J].中华精神科杂志,2010,43(1):27.
[3]孟凤华,李国兰,冷树东,等.盐酸哌罗匹隆片治疗首发精神分裂症30例临床观察[J].中国民康医学,2010,22(9):1119-1120.
[4]张波,王雪,曹毅,等.盐酸哌罗匹隆片与利培酮片治疗232例精神分裂症的疗效比较[J].华西药学杂志,2007,4(6):102-108.
[5]余雪芹,蒋国庆,高芳.国产哌罗匹隆治疗精神分裂症的临床研究[J].重庆医学,2011,40(12):16804.
[6]朱桂东,徐松泉,周云芳.哌罗匹隆与奎硫平治疗首发精神分裂症临床对照[J].医药导报,2011,30(14):477-478.
[7]张映虹.盐酸哌罗匹隆治疗首发精神分裂症患者35例临床效果分析[J].中国实用医药,2012,17(17):153-154.
[8]朱国辉,杨娟,朱建平,等.帕利哌酮缓释片与哌罗匹隆治疗首发精神分裂症患者的对照研究[J].临床精神医学杂志,2013,23(5):329-329.
[2]宋梓祥,涂德华,潘佳,等.奥氮平与利培酮治疗难治性精神分裂症的对照研究[J].中华精神科杂志,2010,43(1):27.
[3]孟凤华,李国兰,冷树东,等.盐酸哌罗匹隆片治疗首发精神分裂症30例临床观察[J].中国民康医学,2010,22(9):1119-1120.
[4]张波,王雪,曹毅,等.盐酸哌罗匹隆片与利培酮片治疗232例精神分裂症的疗效比较[J].华西药学杂志,2007,4(6):102-108.
[5]余雪芹,蒋国庆,高芳.国产哌罗匹隆治疗精神分裂症的临床研究[J].重庆医学,2011,40(12):16804.
[6]朱桂东,徐松泉,周云芳.哌罗匹隆与奎硫平治疗首发精神分裂症临床对照[J].医药导报,2011,30(14):477-478.
[7]张映虹.盐酸哌罗匹隆治疗首发精神分裂症患者35例临床效果分析[J].中国实用医药,2012,17(17):153-154.
[8]朱国辉,杨娟,朱建平,等.帕利哌酮缓释片与哌罗匹隆治疗首发精神分裂症患者的对照研究[J].临床精神医学杂志,2013,23(5):329-329.